Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Legend Biotech (LEGN) Net Income towards Common Stockholders (2019 - 2025)

Historic Net Income towards Common Stockholders for Legend Biotech (LEGN) over the last 7 years, with Q3 2025 value amounting to -$38.5 million.

  • Legend Biotech's Net Income towards Common Stockholders rose 6931.32% to -$38.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$263.6 million, marking a year-over-year increase of 3904.37%. This contributed to the annual value of -$177026.0 for FY2024, which is 6584.18% up from last year.
  • Legend Biotech's Net Income towards Common Stockholders amounted to -$38.5 million in Q3 2025, which was up 6931.32% from -$124.2 million recorded in Q2 2025.
  • Legend Biotech's Net Income towards Common Stockholders' 5-year high stood at $26284.0 during Q4 2024, with a 5-year trough of -$199.1 million in Q2 2023.
  • For the 5-year period, Legend Biotech's Net Income towards Common Stockholders averaged around -$95.8 million, with its median value being -$100.9 million (2025).
  • In the last 5 years, Legend Biotech's Net Income towards Common Stockholders plummeted by 3557017.6% in 2022 and then surged by 11814.97% in 2024.
  • Legend Biotech's Net Income towards Common Stockholders (Quarter) stood at -$88.3 million in 2021, then plummeted by 53.82% to -$135.9 million in 2022, then surged by 99.89% to -$144818.0 in 2023, then surged by 118.15% to $26284.0 in 2024, then crashed by 146413.35% to -$38.5 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$38.5 million for Q3 2025, versus -$124.2 million for Q2 2025 and -$100.9 million for Q1 2025.